{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:29:56Z","timestamp":1791350996012,"version":"4.3.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","award":["GC229060"],"award-info":[{"award-number":["GC229060"]}],"id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA00874"],"award-info":[{"award-number":["P30 CA00874"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA164568-01A1"],"award-info":[{"award-number":["R21 CA164568-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PR101053"],"award-info":[{"award-number":["PR101053"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["LC110202"],"award-info":[{"award-number":["LC110202"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC132124"],"award-info":[{"award-number":["BC132124"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joanne and John DallePezze Foundation"},{"DOI":"10.13039\/100016228","name":"Derfner Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016228","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mr. William H. Goodwin and Alice Goodwin"},{"DOI":"10.13039\/100004436","name":"Commonwealth Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Experimental Therapeutics Center"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.trsl.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T13:30:55Z","timestamp":1493213455000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["CAR T-cell therapy for lung cancer and malignant pleural mesothelioma"],"prefix":"10.1016","volume":"187","author":[{"given":"Masha","family":"Zeltsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3864-7980","authenticated-orcid":false,"given":"Jordan","family":"Dozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ngai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2017.04.004_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.trsl.2017.04.004_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.trsl.2017.04.004_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S2213-2600(14)70259-0","article-title":"ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy","volume":"2","author":"Rosell","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib4","first-page":"79","article-title":"Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints","volume":"12","author":"Karachaliou","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2012.45.2052","article-title":"Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3\/CD3 ratio are independent predictors of recurrence","volume":"31","author":"Suzuki","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/JTO.0000000000000617","article-title":"Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ neutrophil\/CD20+ lymphocyte ratio as an independent prognostic factor","volume":"10","author":"Kadota","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.trsl.2017.04.004_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.trsl.2017.04.004_bib9","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2017.04.004_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.trsl.2017.04.004_bib12","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib13","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2017.04.004_bib15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.trsl.2017.04.004_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.trsl.2017.04.004_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.trsl.2017.04.004_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2017.04.004_bib19","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.trsl.2017.04.004_bib20","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib21","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2017.04.004_bib24","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.04.004_bib25","first-page":"466","article-title":"Mesothelin-targeted immunotherapies for malignant pleural mesothelioma","volume":"1","author":"Villena-Vargas","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.trsl.2017.04.004_bib26","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib27","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma","volume":"21","author":"Rizk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.trsl.2017.04.004_bib29","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2017.04.004_bib30","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib31","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib34","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib35","doi-asserted-by":"crossref","first-page":"e26722","DOI":"10.1371\/journal.pone.0026722","article-title":"An in\u00a0vivo platform for tumor biomarker assessment","volume":"6","author":"Servais","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2017.04.004_bib36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s13277-012-0344-0","article-title":"The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer","volume":"33","author":"Lee","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.trsl.2017.04.004_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2017.04.004_bib38","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/JTO.0000000000000379","article-title":"NSCLC and HER2: between lights and shadows","volume":"9","author":"Ricciardi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib39","first-page":"CD010383","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","author":"Greenhalgh","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trsl.2017.04.004_bib40","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.trsl.2017.04.004_bib41","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2017.04.004_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trsl.2017.04.004_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14653240600620176","article-title":"Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma","volume":"8","author":"Cooper","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.trsl.2017.04.004_bib45","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in\u00a0vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.04.004_bib46","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib47","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib48","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib50","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-12-3874","article-title":"Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases","volume":"73","author":"Riese","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib51","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib52","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-08-0356","article-title":"Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers","volume":"14","author":"Wallace","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib53","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.04.004_bib54","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.trsl.2017.04.004_bib55","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.04.004_bib56","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2017.04.004_bib57","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2017.04.004_bib58","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib59","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trsl.2017.04.004_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib61","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2017.04.004_bib62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2017.04.004_bib63","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/1078-0432.CCR-14-2998","article-title":"K562-Derived whole-cell vaccine enhances antitumor responses of CAR-redirected Virus-specific cytotoxic T lymphocytes in\u00a0vivo","volume":"21","author":"Caruana","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524417301718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524417301718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:35:28Z","timestamp":1761827728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524417301718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":63,"alternative-id":["S1931524417301718"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2017.04.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}